"Epothilones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).
| Descriptor ID |
D034261
|
| MeSH Number(s) |
D02.540.576.500.984
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Epothilones".
Below are MeSH descriptors whose meaning is more specific than "Epothilones".
This graph shows the total number of publications written about "Epothilones" by people in this website by year, and whether "Epothilones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 2 | 0 | 2 |
| 2003 | 3 | 0 | 3 |
| 2004 | 2 | 1 | 3 |
| 2006 | 2 | 0 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 1 | 4 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 1 | 3 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epothilones" by people in Profiles.
-
Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. Clin Breast Cancer. 2015 Oct; 15(5):325-31.
-
Current use of drugs affecting the central nervous system for chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review. Support Care Cancer. 2015 Feb; 23(2):513-24.
-
Profile and potential of ixabepilone in the treatment of pancreatic cancer. Drug Des Devel Ther. 2014; 8:923-30.
-
Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.
-
Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of ?III-tubulin expression as a predictive marker. Oncologist. 2013; 18(7):787-94.
-
Locoregional interaction of ixabepilone (ixempra) after breast cancer radiation. Oncologist. 2013; 18(3):265-70.
-
A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. Cancer. 2013 May 01; 119(9):1683-9.
-
Managing ixabepilone adverse events with dose reduction. Clin Breast Cancer. 2013 Feb; 13(1):1-6.
-
Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. Clin Breast Cancer. 2012 Aug; 12(4):240-6.
-
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group. Clin Genitourin Cancer. 2012 Jun; 10(2):99-105.